Expression profiling of ion channel genes predicts clinical outcome in breast cancer

Jae Hong Ko, Eun A. Ko, Wanjun Gu, Inja Lim, Hyoweon Bang, Tong Zhou

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Background: Ion channels play a critical role in a wide variety of biological processes, including the development of human cancer. However, the overall impact of ion channels on tumorigenicity in breast cancer remains controversial.Methods: We conduct microarray meta-analysis on 280 ion channel genes. We identify candidate ion channels that are implicated in breast cancer based on gene expression profiling. We test the relationship between the expression of ion channel genes and p53 mutation status, ER status, and histological tumor grade in the discovery cohort. A molecular signature consisting of ion channel genes (IC30) is identified by Spearman's rank correlation test conducted between tumor grade and gene expression. A risk scoring system is developed based on IC30. We test the prognostic power of IC30 in the discovery and seven validation cohorts by both Cox proportional hazard regression and log-rank test.Results: 22, 24, and 30 ion channel genes are found to be differentially expressed with a change in p53 mutation status, ER status, and tumor histological grade in the discovery cohort. We assign the 30 tumor grade associated ion channel genes as the IC30 gene signature. We find that IC30 risk score predicts clinical outcome (P < 0.05) in the discovery cohort and 6 out of 7 validation cohorts. Multivariate and univariate tests conducted in two validation cohorts indicate that IC30 is a robust prognostic biomarker, which is independent of standard clinical and pathological prognostic factors including patient age, lymph node status, tumor size, tumor grade, estrogen and progesterone receptor status, and p53 mutation status.Conclusions: We identified a molecular gene signature IC30, which represents a promising diagnostic and prognostic biomarker in breast cancer. Our results indicate that information regarding the expression of ion channels in tumor pathology could provide new targets for therapy in human cancers.

Original languageEnglish (US)
Article number106
JournalMolecular Cancer
Volume12
Issue number1
DOIs
StatePublished - Sep 22 2013
Externally publishedYes

Fingerprint

Ion Channels
Breast Neoplasms
Genes
Neoplasms
Mutation
Biomarkers
Biological Phenomena
p53 Genes
Human Development
Gene Expression Profiling
Progesterone Receptors
Microarray Analysis
Estrogen Receptors
Meta-Analysis
Lymph Nodes
Pathology
Gene Expression

Keywords

  • Breast cancer
  • Estrogen receptor
  • Gene expression
  • Ion channel
  • Microarray
  • Molecular signature
  • p53

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Oncology

Cite this

Expression profiling of ion channel genes predicts clinical outcome in breast cancer. / Ko, Jae Hong; Ko, Eun A.; Gu, Wanjun; Lim, Inja; Bang, Hyoweon; Zhou, Tong.

In: Molecular Cancer, Vol. 12, No. 1, 106, 22.09.2013.

Research output: Contribution to journalArticle

Ko, Jae Hong ; Ko, Eun A. ; Gu, Wanjun ; Lim, Inja ; Bang, Hyoweon ; Zhou, Tong. / Expression profiling of ion channel genes predicts clinical outcome in breast cancer. In: Molecular Cancer. 2013 ; Vol. 12, No. 1.
@article{5ddb8ab7fedd466aa945220c7093345d,
title = "Expression profiling of ion channel genes predicts clinical outcome in breast cancer",
abstract = "Background: Ion channels play a critical role in a wide variety of biological processes, including the development of human cancer. However, the overall impact of ion channels on tumorigenicity in breast cancer remains controversial.Methods: We conduct microarray meta-analysis on 280 ion channel genes. We identify candidate ion channels that are implicated in breast cancer based on gene expression profiling. We test the relationship between the expression of ion channel genes and p53 mutation status, ER status, and histological tumor grade in the discovery cohort. A molecular signature consisting of ion channel genes (IC30) is identified by Spearman's rank correlation test conducted between tumor grade and gene expression. A risk scoring system is developed based on IC30. We test the prognostic power of IC30 in the discovery and seven validation cohorts by both Cox proportional hazard regression and log-rank test.Results: 22, 24, and 30 ion channel genes are found to be differentially expressed with a change in p53 mutation status, ER status, and tumor histological grade in the discovery cohort. We assign the 30 tumor grade associated ion channel genes as the IC30 gene signature. We find that IC30 risk score predicts clinical outcome (P < 0.05) in the discovery cohort and 6 out of 7 validation cohorts. Multivariate and univariate tests conducted in two validation cohorts indicate that IC30 is a robust prognostic biomarker, which is independent of standard clinical and pathological prognostic factors including patient age, lymph node status, tumor size, tumor grade, estrogen and progesterone receptor status, and p53 mutation status.Conclusions: We identified a molecular gene signature IC30, which represents a promising diagnostic and prognostic biomarker in breast cancer. Our results indicate that information regarding the expression of ion channels in tumor pathology could provide new targets for therapy in human cancers.",
keywords = "Breast cancer, Estrogen receptor, Gene expression, Ion channel, Microarray, Molecular signature, p53",
author = "Ko, {Jae Hong} and Ko, {Eun A.} and Wanjun Gu and Inja Lim and Hyoweon Bang and Tong Zhou",
year = "2013",
month = "9",
day = "22",
doi = "10.1186/1476-4598-12-106",
language = "English (US)",
volume = "12",
journal = "Molecular Cancer",
issn = "1476-4598",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Expression profiling of ion channel genes predicts clinical outcome in breast cancer

AU - Ko, Jae Hong

AU - Ko, Eun A.

AU - Gu, Wanjun

AU - Lim, Inja

AU - Bang, Hyoweon

AU - Zhou, Tong

PY - 2013/9/22

Y1 - 2013/9/22

N2 - Background: Ion channels play a critical role in a wide variety of biological processes, including the development of human cancer. However, the overall impact of ion channels on tumorigenicity in breast cancer remains controversial.Methods: We conduct microarray meta-analysis on 280 ion channel genes. We identify candidate ion channels that are implicated in breast cancer based on gene expression profiling. We test the relationship between the expression of ion channel genes and p53 mutation status, ER status, and histological tumor grade in the discovery cohort. A molecular signature consisting of ion channel genes (IC30) is identified by Spearman's rank correlation test conducted between tumor grade and gene expression. A risk scoring system is developed based on IC30. We test the prognostic power of IC30 in the discovery and seven validation cohorts by both Cox proportional hazard regression and log-rank test.Results: 22, 24, and 30 ion channel genes are found to be differentially expressed with a change in p53 mutation status, ER status, and tumor histological grade in the discovery cohort. We assign the 30 tumor grade associated ion channel genes as the IC30 gene signature. We find that IC30 risk score predicts clinical outcome (P < 0.05) in the discovery cohort and 6 out of 7 validation cohorts. Multivariate and univariate tests conducted in two validation cohorts indicate that IC30 is a robust prognostic biomarker, which is independent of standard clinical and pathological prognostic factors including patient age, lymph node status, tumor size, tumor grade, estrogen and progesterone receptor status, and p53 mutation status.Conclusions: We identified a molecular gene signature IC30, which represents a promising diagnostic and prognostic biomarker in breast cancer. Our results indicate that information regarding the expression of ion channels in tumor pathology could provide new targets for therapy in human cancers.

AB - Background: Ion channels play a critical role in a wide variety of biological processes, including the development of human cancer. However, the overall impact of ion channels on tumorigenicity in breast cancer remains controversial.Methods: We conduct microarray meta-analysis on 280 ion channel genes. We identify candidate ion channels that are implicated in breast cancer based on gene expression profiling. We test the relationship between the expression of ion channel genes and p53 mutation status, ER status, and histological tumor grade in the discovery cohort. A molecular signature consisting of ion channel genes (IC30) is identified by Spearman's rank correlation test conducted between tumor grade and gene expression. A risk scoring system is developed based on IC30. We test the prognostic power of IC30 in the discovery and seven validation cohorts by both Cox proportional hazard regression and log-rank test.Results: 22, 24, and 30 ion channel genes are found to be differentially expressed with a change in p53 mutation status, ER status, and tumor histological grade in the discovery cohort. We assign the 30 tumor grade associated ion channel genes as the IC30 gene signature. We find that IC30 risk score predicts clinical outcome (P < 0.05) in the discovery cohort and 6 out of 7 validation cohorts. Multivariate and univariate tests conducted in two validation cohorts indicate that IC30 is a robust prognostic biomarker, which is independent of standard clinical and pathological prognostic factors including patient age, lymph node status, tumor size, tumor grade, estrogen and progesterone receptor status, and p53 mutation status.Conclusions: We identified a molecular gene signature IC30, which represents a promising diagnostic and prognostic biomarker in breast cancer. Our results indicate that information regarding the expression of ion channels in tumor pathology could provide new targets for therapy in human cancers.

KW - Breast cancer

KW - Estrogen receptor

KW - Gene expression

KW - Ion channel

KW - Microarray

KW - Molecular signature

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=84884302148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884302148&partnerID=8YFLogxK

U2 - 10.1186/1476-4598-12-106

DO - 10.1186/1476-4598-12-106

M3 - Article

C2 - 24053408

AN - SCOPUS:84884302148

VL - 12

JO - Molecular Cancer

JF - Molecular Cancer

SN - 1476-4598

IS - 1

M1 - 106

ER -